5.94
+4.39%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Anteris Technologies Global
From its filings with the US Securities and Exchange Commission
Anteris Technologies Global is based in Eagan, Minnesota and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker AVR. The SEC classifies its business as orthopedic, prosthetic & surgical appliances & supplies. In the fiscal year to 31 December 2025, it reported revenue of $1.9m and a net loss of $94.1m. At that date it held total assets of $23.0m and shareholders' equity of −$93,000.
Anteris is a structural heart company dedicated to revolutionizing cardiac care by pioneering science-driven and measurable advancements to restore heart valve patients to healthy function. Our lead product, the DurAVR® THV System, was designed in collaboration with the world’s leading interventional cardiologists and cardiac surgeons to treat aortic stenosis — a potentially life-threatening condition resulting from a narrowing of the aortic valve. The balloon-expandable DurAVR® THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. Our DurAVR® THV System consists of a single-piece, biomimetic valve made with our proprietary ADAPT® tissue-enhancing technology and deployed with our balloon expandable ComASUR® Delivery System. ADAPT® is our proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. Our patented ADAPT® tissue has been clinically demonstrated to be calcium free for up to 10 years post-procedure, according to Performance of the ADAPT-Treated CardioCel® Scaffold in Pediatric Patients With Congenital Cardiac Anomalies: Medium to Long-Term Outcomes, published by William Neethling et. al., and has been distributed for use in over 55,000 patients globally in other indications.
Quoted from its 10-K, filed 26 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 13 Dec 2024
- Employees
- 174
- Head office
- 860 BLUE GENTIAN ROAD, EAGAN, MN, 55121
- Incorporated in
- DE
- Classification
- Orthopedic, Prosthetic & Surgical Appliances & Supplies
- Filer status
- <br>Emerging growth company
Leadership
Pay as last reported
- Mr. John SeabergIndependent Chairman of the Board$517,389
- Mr. David St DenisPresident, Director, since 2017$3.9m
- Mr. Wayne PatersonChief Executive Officer, Vice Chairman of the Board, since 2016$3.0m
- Mr. Matthew McdonnellChief Financial Officer$1.0m
- Mr. Stephen DenaroCompany Secretary, Non-Executive Director, since 2018$360,089
- Mr. Gregory MossDirector
- Mr. David RobertsDirector
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Anteris Technologies Global Corp employs 174 full-time employees in Health Care Equipment & Supplies.
- DurAVR Transcatheter Heart Valve addresses aortic stenosis with native-shaped biomimetic design.
- ADAPT technology reengineers xenograft tissue into pure collagen bioscaffold for medical devices.
Weaknesses
- Anteris Technologies Global Corp has 138 full-time employees as of IPO listing date.
- The company's IPO occurred on 13 December 2024, a recent market entry.
- ComASUR Transfemoral Delivery System is still under development.
Opportunities
- Anteris Technologies Global Corp targets aortic stenosis patients with failed valves for valve-in-valve treatment.
- The Health Care Equipment & Supplies industry shows growth potential in medical device innovation.
- Eagan, Minnesota serves as headquarters for Health Care sector operations.
Threats
- Anteris Technologies Global Corp faces competition in the Health Care Equipment & Supplies industry.
- The company's IPO on 13 December 2024 may face market volatility risks.
- DurAVR THV technology requires regulatory approvals for broader market access.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.